EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE

被引：0
|
作者：
Villa, J. C. [1 ]
Espinosa, J. [1 ]
Gomez, R. [1 ]
Sanchez, V [1 ]
Lopez, R. [1 ]
Galan, R. [1 ]
Pineda, M. D. [1 ]
Perez, M. [1 ]
机构：
[1] Ciudad Real Univ Gen Hosp, Ciudad Real, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.236
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A816 / A817
页数：2
相关论文
共 50 条
  • [21] Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer
    Shameem, Raji
    Hamid, Muhammad Saad
    Xu, Kevin Y.
    Wu, Shenhong
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 64 - 72
  • [22] No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer
    Tanaka, Masatoshi
    Kimura, Takahiro
    Iwamura, Yumina
    Enei, Yuki
    Iwamoto, Yuya
    Imai, Yu
    Inaba, Yuzo
    Matsukawa, Akihiro
    Onuma, Hajime
    Ito, Kagenori
    Mori, Keiichiro
    Sasaki, Hiroshi
    Miki, Jun
    Furuta, Akira
    Miki, Kenta
    Egawa, Shin
    PROSTATE, 2019, 79 (14) : 1604 - 1610
  • [23] Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel
    Buttigliero, Consuelo
    Tucci, Marcello
    Vignani, Francesca
    Di Stefano, Rosario F.
    Leone, Gianmarco
    Zichi, Clizia
    Pignataro, Daniele
    Lacidogna, Gaetano
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio, V
    Di Maio, Massimo
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : 318 - 324
  • [24] Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model
    Bass, Roman
    Roberto, Domenica
    Wang, Daniel Zongjie
    Cantu, Fernando Pena
    Mohamadi, Reza M.
    Kelley, Shana O.
    Klotz, Laurence
    Venkateswaran, Vasundara
    ANTICANCER RESEARCH, 2019, 39 (01) : 113 - 118
  • [25] Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
    Antonarakis, E. S.
    Armstrong, A. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2011, 14 (03) : 192 - 205
  • [26] COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL TREATMENT IN JAPAN
    Shibahara, H.
    Shiroiwa, T.
    Nakamura, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A416
  • [27] Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2017, 197 (01) : 155 - 156
  • [28] Phospholipids as Indicators of Docetaxel-Resistant Castration-Resistant Prostate Cancer
    Ingram, Lishann M.
    Mansoura, Maryam
    Cummings, Brian S.
    FASEB JOURNAL, 2019, 33
  • [29] Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: Is there a clinical benefit?
    Kongsted, Per
    Svane, Inge Marie
    Lindberg, Henriette
    Daugaard, Gedske
    Sengelov, Lisa
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (11) : 494.e15 - 494.e20
  • [30] Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
    Mahon, K. L.
    Lin, H-M
    Castillo, L.
    Lee, B. Y.
    Lee-Ng, M.
    Chatfield, M. D.
    Chiam, K.
    Breit, S. N.
    Brown, D. A.
    Molloy, M. P.
    Marx, G. M.
    Pavlakis, N.
    Boyer, M. J.
    Stockler, M. R.
    Daly, R. J.
    Henshall, S. M.
    Horvath, G.
    BRITISH JOURNAL OF CANCER, 2015, 112 (08) : 1340 - 1348
12345